Table II.
Adherence, discontinuation, switch, and restart outcomes*
| Outcome | All | Adalimumab | Etanercept | Infliximab | Ustekinumab |
|---|---|---|---|---|---|
| Overall | |||||
| N | 2707 | 1084 | 1025 | 318 | 280 |
| PDC, mean (SD) | 0.61 (0.31) | 0.63 (0.31) | 0.56 (0.31) | 0.66 (0.32) | 0.70 (0.28) |
| Adherent (PDC ≥0.80) | 37.7% | 40.7% | 29.4% | 49.4% | 43.2% |
| Discontinued | 45.5% | 43.4% | 51.7% | 42.5% | 35.0% |
| Switched | 8.0% | 9.0% | 9.5% | 5.0% | 1.8% |
| Restarted | 9.2% | 6.6% | 9.9% | 10.4% | 15.0% |
| With index biologic | 7.6% | 5.1% | 8.4% | 6.9% | 15.0% |
| With different biologic | 1.6% | 1.5% | 1.5% | 3.5% | 0.0% |
| Other discontinuer | 28.4% | 27.8% | 32.4% | 27.0% | 18.2% |
| Age <65 y | |||||
| N | 1325 | 593 | 519 | 89 | 124 |
| PDC, mean (SD) | 0.62 (0.30) | 0.65 (0.30) | 0.57 (0.34) | 0.59 (0.34) | 0.73 (0.27) |
| Adherent (PDC ≥0.80) | 37.7% | 43.3% | 29.1% | 40.4% | 45.2% |
| Discontinued | 44.1% | 40.6% | 50.3% | 49.4% | 30.6% |
| Switched | 9.5% | 9.1% | 11.8% | 7.9% | 3.2% |
| Restarted | 9.8% | 7.3% | 10.4% | 14.6% | 15.3% |
| With index biologic | 7.8% | 5.1% | 8.7% | 10.1% | 15.3% |
| With different biologic | 2.0% | 2.2% | 1.7% | 4.5% | 0.0% |
| Other discontinuer | 24.8% | 24.3% | 28.1% | 27.0% | 12.1% |
| Age ≥65 y | |||||
| N | 1382 | 491 | 506 | 229 | 156 |
| PDC, mean (SD) | 0.61 (0.32) | 0.60 (0.32) | 0.55 (0.32) | 0.69 (0.31) | 0.68 (0.28) |
| Adherent (PDC ≥0.80) | 37.6% | 37.5% | 29.6% | 52.8% | 41.7% |
| Discontinued | 47.0% | 46.6% | 53.2% | 39.7% | 38.5% |
| Switched | 6.5% | 9.0% | 7.1% | 3.9% | 0.6% |
| Restarted | 8.6% | 5.7% | 9.3% | 8.8% | 14.7% |
| With index biologic | 7.4% | 5.1% | 8.1% | 5.7% | 14.7% |
| With different biologic | 1.2% | 0.6% | 1.2% | 3.1% | 0.0% |
| Other discontinuer | 31.9% | 32.0% | 36.8% | 27.1% | 23.1% |
| No medical claims for psoriatic arthritis | |||||
| N | 1720 | 719 | 715 | 72 | 214 |
| PDC, mean (SD) | 0.60 (0.31) | 0.63 (0.31) | 0.55 (0.30) | 0.61 (0.32) | 0.69 (0.29) |
| Adherent (PDC ≥0.80) | 35.6% | 42.0% | 26.2% | 41.7% | 43.9% |
| Discontinued | 46.6% | 42.3% | 54.0% | 47.2% | 36.0% |
| Switched | 8.4% | 9.6% | 9.5% | 4.2% | 2.3% |
| Restarted | 9.2% | 6.4% | 9.9% | 13.9% | 14.0% |
| With index biologic | 7.7% | 4.7% | 8.5% | 9.7% | 14.0% |
| With different biologic | 1.5% | 1.7% | 1.4% | 4.2% | 0.0% |
| Other discontinuer | 29.0% | 26.3% | 34.5% | 29.2% | 19.6% |
PDC, Proportion of days covered.
*
Discontinuation defined as continuous gap of 90 d. Switch indicates beginning treatment with a new biologic within 90 d of discontinuing the index biologic. Restart indicates resuming treatment with the index biologic or a new biologic after 90 d of discontinuing the index biologic. Other indicates no resumption of treatment before the end of the follow-up period.